choriogonadotropin alfa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5149	177073-44-8

Description:

Molecule	Description
Synonyms: choriogonadotropin alfa ovidrel ovitrelle	Choriogonadotropin alfa, is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge. In pregnancy, hCG, secreted by the placenta, maintains the viability of the corpus luteum to provide the continued secretion of estrogen and progesterone necessary to support the first trimester of pregnancy. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

choriogonadotropin alfa
ovidrel
ovitrelle

Choriogonadotropin alfa, is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge. In pregnancy, hCG, secreted by the placenta, maintains the viability of the corpus luteum to provide the continued secretion of estrogen and progesterone necessary to support the first trimester of pregnancy.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.25	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 20, 2000	FDA	EMD SERONO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	5188.84	46.59	732	3196	3282	63481812
Ascites	812.87	46.59	229	3699	40499	63444595
Maternal exposure before pregnancy	202.97	46.59	54	3874	7549	63477545
Ovarian haemorrhage	202.81	46.59	32	3896	306	63484788
Abdominal distension	167.34	46.59	89	3839	86526	63398568
Pelvic fluid collection	147.08	46.59	28	3900	848	63484246
Adnexal torsion	144.89	46.59	25	3903	429	63484665
Inappropriate schedule of product administration	133.89	46.59	82	3846	103883	63381211
Ovarian enlargement	129.44	46.59	23	3905	471	63484623
Haemoperitoneum	120.39	46.59	29	3899	2712	63482382
Pleural effusion	96.23	46.59	64	3864	93146	63391948
Abortion spontaneous	95.23	46.59	50	3878	47145	63437949
Abdominal pain lower	81.23	46.59	37	3891	25641	63459453
Multiple pregnancy	76.24	46.59	11	3917	53	63485041
Effusion	69.41	46.59	17	3911	1701	63483393
Intra-abdominal haemorrhage	68.04	46.59	18	3910	2451	63482643
Ectopic pregnancy	67.35	46.59	18	3910	2549	63482545
Infrequent bowel movements	58.32	46.59	14	3914	1288	63483806
Abdominal pain	55.80	46.59	79	3849	293377	63191717
Ovarian cyst ruptured	54.26	46.59	13	3915	1186	63483908
Poor response to ovulation induction	52.15	46.59	6	3922	0	63485094
Haemoconcentration	46.64	46.59	8	3920	132	63484962

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product packaging quantity issue	237.71	96.29	35	527	894	34955475
No adverse event	208.18	96.29	52	510	22875	34933494
Product dose omission issue	169.40	96.29	65	497	119646	34836723

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	4658.71	48.57	630	2871	2941	79737946
Ascites	704.45	48.57	218	3283	75344	79665543
Ovarian haemorrhage	200.51	48.57	30	3471	286	79740601
Pelvic fluid collection	158.56	48.57	28	3473	791	79740096
Adnexal torsion	150.42	48.57	24	3477	359	79740528
Ovarian enlargement	144.09	48.57	23	3478	345	79740542
Abdominal distension	138.45	48.57	78	3423	119572	79621315
Maternal exposure before pregnancy	111.81	48.57	28	3473	4345	79736542
Haemoperitoneum	97.18	48.57	25	3476	4318	79736569
Pleural effusion	85.83	48.57	62	3439	145200	79595687
Multiple pregnancy	75.09	48.57	10	3491	36	79740851
Effusion	70.93	48.57	17	3484	2197	79738690
Abdominal pain lower	69.77	48.57	32	3469	31750	79709137
Product packaging quantity issue	62.60	48.57	14	3487	1335	79739552
Ovarian cyst ruptured	61.50	48.57	13	3488	953	79739934
Abdominal pain	56.47	48.57	77	3424	389492	79351395
No adverse event	53.31	48.57	28	3473	37164	79703723
Intra-abdominal haemorrhage	50.04	48.57	15	3486	4525	79736362

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03GA08	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM GONADOTROPINS AND OTHER OVULATION STIMULANTS Gonadotropins
FDA CS	M0009540	Gonadotropins
FDA EPC	N0000175838	Gonadotropin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ulcerative colitis	indication	64766004	DOID:8577

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Lutropin-choriogonadotropic hormone receptor	GPCR	P22888	LSHR_HUMAN	AGONIST				CHEMBL	CHEMBL

External reference:

ID	Source
6413W06WR3	UNII
4021245	VANDF
C0937609	UMLSCUI
CHEMBL1201464	ChEMBL_ID
D03478	KEGG_DRUG
DB00097	DRUGBANK_ID
7473	INN_ID
C412828	MESH_SUPPLEMENTAL_RECORD_UI
283550	RXNORM
15777	MMSL
38355	MMSL
009029	NDDF
129494006	SNOMEDCT_US
391878002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ovidrel	HUMAN PRESCRIPTION DRUG LABEL	1	44087-1150	INJECTION, SOLUTION	250 ug	SUBCUTANEOUS	BLA	23 sections